



CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®

5th Edition

VET01S

Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

This document includes updated tables for the Clinical and Laboratory Standards Institute veterinary antimicrobial susceptibility testing standard VET01.

A CLSI supplement for global application.

Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

www.clsi.org

standard@clsi.org

Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Brian V. Lubbers, DVM, PhD, DACVCP
Dubraska V. Diaz-Campos, DVM, PhD
Stefan Schwarz, DVM
Robert Bowden, BS
Claire R. Burbick, DVM, PhD, DACVM
Virginia R. Fajt, DVM, PhD, DACVCP
Mark Fielder, PhD
Lacie Gunnett, BS
Nicole M. Holliday, BA
Cecile Kerdraon, MS
Cory Langston, DVM, PhD
Sara D. Lawhon, DVM, PhD, DACVM

Xian-Zhi Li, PhD
Marilyn N. Martinez, PhD
Ron A. Miller, MS, PhD
Ian Morrissey, BSc, MBA, PhD, FRSM
Mark G. Papich, DVM, MS
Shabbir Simjee, MSc, PhD
Virginia Sinnott-Stutzman, DVM, DACVECC
Michael T. Sweeney, MS
Maria M. Traczewski, BS, MT(ASCP)
Darren Trott, PhD
S. Steve Yan, PhD

Abstract

The data in the tables are valid only if the methodologies in CLSI document VET01¹ are followed. This standard contains information about disk and dilution susceptibility test procedures for aerobic and facultatively anaerobic bacteria. Clinicians need information from the microbiology laboratory for treating and/or confirming treatment decisions for their patients with bacterial infections and depend heavily on this information for treating their seriously ill patients. The clinical importance of antimicrobial susceptibility test results demands that these tests be performed under optimal conditions and that laboratories have the capability to interpret results based on the most current breakpoints and interpretive categories for antimicrobial agents used in veterinary medicine.

The tables presented in VET01S represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in VET01.¹ Users should replace previously published tables with these new tables. Changes in the tables since the previous edition appear in boldface type.

Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 5th ed. CLSI supplement VET01S (ISBN 978-1-68440-092-8 [Print]; ISBN 978-1-68440-093-5 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2020.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org.

**If you or your organization is not a member and would like to become one,
or to request a copy of the catalog, contact us at:**

P: +1.610.688.0100 **F:** +1.610.688.0700 **E:** customerservice@cls.org **W:** www.clsi.org



**CLINICAL AND
LABORATORY
STANDARDS
INSTITUTE®**

Copyright ©2020 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation

CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals*. 5th ed. CLSI supplement VET01S. Clinical and Laboratory Standards Institute; 2020.

Previous Editions:

May 2004, July 2013, June 2015, June 2018

VET01-Ed5-S-Ed5
ISBN 978-1-68440-092-8 (Print)
ISBN 978-1-68440-093-5 (Electronic)
ISSN 1558-6502 (Print)
ISSN 2162-2914 (Electronic)

Volume 40, Number 13

Committee Membership

Subcommittee on Veterinary Antimicrobial Susceptibility Testing

Brian V. Lubbers, DVM, PhD,
DACVCP
Chairholder
Kansas State Veterinary Diagnostic
Laboratory
USA

Dubrasca V. Diaz-Campos, DVM,
PhD
Vice-Chairholder
College of Veterinary Medicine,
Veterinary Medical Center,
The Ohio State University
USA

Stefan Schwarz, DVM
Committee Secretary
Freie Universität Berlin
Germany

Claire R. Burbick, DVM, PhD, DACVM
Washington State University
USA

Mark Fielder, PhD
School of Life Science,
Kingston University London
United Kingdom

Nicole M. Holliday, BA
Thermo Fisher Scientific
USA

Cory Langston, DVM, PhD
Mississippi State University
USA

Sara D. Lawhon, DVM, PhD, DACVM
Texas A & M University
USA

Xian-Zhi Li, PhD
Health Canada Veterinary Drugs
Directorate
Canada

Marilyn N. Martinez, PhD
FDA Center for Veterinary
Medicine
USA

Ian Morrissey, BSc, MBA, PhD,
FRSM
IHMA Europe Sarl
Switzerland

Shabbir Simjee, MSc, PhD
Elanco Animal Health
United Kingdom

Michael T. Sweeney, MS
Zoetis
USA

Darren Trott, PhD
School of Animal and Veterinary
Sciences, University of Adelaide,
Australia

Working Group on Editorial/VAST Breakpoint Tables

Michael T. Sweeney, MS
Chairholder
Zoetis
USA

Robert Bowden, BS
Committee Secretary
Beth Israel Deaconess Medical
Center
USA

Claire Burbick, DVM, PhD, DACVM
Washington State University
USA

Dubrasca V. Diaz-Campos, DVM, PhD
College of Veterinary Medicine,
Veterinary Medical Center,
The Ohio State University
USA

Virginia R. Fajt, DVM, PhD, DACVCP
Texas A & M University
USA

Cecile Kerdraon, MS
bioMérieux, Inc.
France

Sara Lawhon, DVM, PhD, DACVM
Texas A & M University
USA

Xian-Zhi Li, PhD
Health Canada Veterinary Drugs
Directorate
Canada

Ron A. Miller, MS, PhD
FDA Center for Veterinary Medicine
USA

Mark G. Papich, DVM, MS
College of Veterinary Medicine,
North Carolina State University
USA

Stefan Schwarz, DVM
Freie Universität Berlin
Germany

Maria M. Traczewski, BS,
MT(ASCP)
The Clinical Microbiology
Institute
USA

S. Steve Yan, PhD
FDA Center for Veterinary
Medicine
USA

Staff

Clinical and Laboratory Standards
Institute
USA

Lori T. Moon, MS, MT(ASCP)
Project Manager

Megan L. Tertel, MA, ELS
Editorial Manager

Catherine E.M. Jenkins
Editor

Kristy L. Leirer, MS
Editor

Laura Martin
Editor

Acknowledgment

CLSI and the Subcommittee on Veterinary Antimicrobial Susceptibility Testing gratefully acknowledge the following volunteers for their important contributions to the revision of this document:

Lacie Gunnett, BS
Zoetis
USA

Virginia Sinnott-Stutzman, DVM,
DACVECC
Angell Animal Medical Center (MSPCA)
USA

Contents

Abstract	i
Committee Membership.....	iii
Overview of Changes	viii
Summary of CLSI Processes for Establishing Breakpoints and Quality Control Ranges....	xxvii
CLSI Reference Methods vs Commercial Methods and CLSI vs Regulatory Authority	xxviii
CLSI Veterinary-Specific Breakpoint Additions/Revisions Since January 2019	xxix
Subcommittee on Veterinary Antimicrobial Susceptibility Testing Mission Statement and Responsibilities	xxx
Instructions for Use of Tables.....	1
References	15
Table 1. Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories	16
Table 2A. Zone Diameter and MIC Breakpoints for Enterobacterales	24
Table 2B. Zone Diameter and MIC Breakpoints for <i>Pseudomonas aeruginosa</i>	44
Table 2C-1. Zone Diameter and MIC Breakpoints for <i>Staphylococcus</i> spp. for B-Lactams and B-Lactam Combination Agents	48
Table 2C-2. Zone Diameter and MIC Breakpoints for <i>Staphylococcus</i> spp. for Non-B-Lactams	62
Table 2D. Zone Diameter and MIC Breakpoints for <i>Enterococcus</i> spp.	74
Table 2E. Zone Diameter and MIC Breakpoints for <i>Streptococcus</i> spp.	80
Table 2F. Zone Diameter and MIC Breakpoints for <i>Bordetella bronchiseptica</i>	98
Table 2G. Zone Diameter and MIC Breakpoints for <i>Mannheimia haemolytica</i>	100
Table 2H. Zone Diameter and MIC Breakpoints for <i>Pasteurella multocida</i>	104
Table 2I. Zone Diameter and MIC Breakpoints for <i>Actinobacillus pleuropneumoniae</i>	110
Table 2J. Zone Diameter and MIC Breakpoints for <i>Histophilus somni</i>	114
Table 3. QC Strain Culture Collection Numbers for Antimicrobial Susceptibility Tests ...	118
Table 4A. Disk Diffusion QC Ranges for Nonfastidious Organisms.....	120

.....

Contents (Continued)

Table 4B. Disk Diffusion QC Ranges for Fastidious Organisms	124
Table 4C. Disk Diffusion Reference Guide to QC Frequency	126
Table 4D. Disk Diffusion Troubleshooting Guide	128
Table 5A. MIC QC Ranges for Nonfastidious Organisms	132
Table 5B. MIC QC Ranges for Fastidious Organisms (Broth Dilution Methods).....	134
Table 5C. MIC QC Ranges for Anaerobes (Agar Dilution Method).....	138
Table 5D. MIC QC Ranges for Anaerobes (Broth Microdilution Method).....	140
Table 5E. MIC Reference Guide to QC Frequency	142
Table 5F. MIC Troubleshooting Guide	144
Table 6. Solvents and Diluents for Preparing Stock Solutions of Antimicrobial Agents....	148
Table 7A. Disk Diffusion Tests for Extended-Spectrum β -Lactamases in <i>Klebsiella pneumoniae</i> , <i>Klebsiella oxytoca</i> , <i>Escherichia coli</i> , and <i>Proteus mirabilis</i>	150
Table 7B. Broth Microdilution Tests for Extended-Spectrum β -Lactamases in <i>Klebsiella pneumoniae</i> , <i>Klebsiella oxytoca</i> , <i>Escherichia coli</i> , and <i>Proteus mirabilis</i>	152
Table 7C. Test for Detection of β -Lactamase Production in <i>Staphylococcus</i> spp.	154
Table 7D. Disk Diffusion Test for Prediction of <i>mecA</i> -Mediated Resistance in <i>Staphylococcus</i> spp.	158
Table 7E. Vancomycin Agar Screen for <i>Staphylococcus aureus</i> and <i>Enterococcus</i> spp. ...	160
Table 7F. Test for Detection of Inducible Clindamycin Resistance in <i>Staphylococcus</i> spp., <i>Streptococcus</i> spp. β -Hemolytic Group, and <i>Streptococcus pneumoniae</i>	162
Table 7G. Tests for Detection of High-Level Aminoglycoside Resistance in <i>Enterococcus</i> spp. (Includes Disk Diffusion)	164
Appendix A. Suggestions for Confirming Resistant, Intermediate, or Nonsusceptible Antimicrobial Susceptibility Test Results and Organism Identification	168
Appendix B. Intrinsic Resistance	174
Appendix C. Epidemiological Cutoff Values	182

Contents (Continued)

Appendix D. Dosage Regimens Used to Establish Susceptible Veterinary-Specific Breakpoints	184
Appendix E. QC Strains for Antimicrobial Susceptibility Tests	194
Appendix F. CLSI Veterinary-Specific Breakpoint Additions/Revisions to VET01 Supplements Since 1999	198
Glossary I. Antimicrobial Class and Subclass Designations, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms	206
Glossary II. Abbreviations Commonly Used for Antimicrobial Agents Incorporated Into Disks or Susceptibility Panels	210
Glossary III. List of Identical Abbreviations Used for More Than One Antimicrobial Agent in US Diagnostic Products.....	212
The Quality Management System Approach	214
Related CLSI Reference Materials	215